Impact of molecular therapy on radioactive iodine uptake in patients with oncogene-driven metastatic differentiated thyroid cancer

被引：0
|
作者：
Yang, Adeline T.
Segers, Blair
Caradonio, Olivia
Behl, Supriya
Li, Yimei
Zhuang, Hongming
States, Lisa
Mahajan, Priya
Ketterl, Tyler Garrett
Waguespack, Steven G.
Isaza, Amber
Sisko, Lindsay
Franco, Aime
Bauer, Andrew J.
Laetsch, Theodore Willis
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA USA
[2] Texas Childrens Hosp, Baylor Coll Med, Houston, TX USA
[3] Univ Washington, Seattle Childrens Hosp, Seattle, WA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Thyroid Ctr, Philadelphia, PA USA
[6] Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA USA
[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10078
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sarcoidosis mimicking metastatic thyroid cancer following radioactive iodine therapy
    Myint, Zin W.
    Chow, Robert D.
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2015, 5 (01):
  • [32] Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer
    Hong C.M.
    Ahn B.-C.
    Nuclear Medicine and Molecular Imaging, 2018, 52 (4) : 247 - 253
  • [33] Experiences of low iodine diets in the treatment of differentiated thyroid cancer with radioactive iodine ablation therapy
    Herbert, Georgia
    Searle, Aidan
    England, Clare Yvonne
    Ness, Andy
    Beasley, Matthew
    Haupt-Schott, Ingrid
    Moss, Laura
    Wescott, Judith
    Atkinson, Charlotte
    CLINICAL NUTRITION ESPEN, 2020, 39 : 190 - 197
  • [34] TREATMENT OF METASTATIC THYROID CANCER WITH RADIOACTIVE IODINE
    OZARDA, A
    BENDER, MA
    NEW YORK STATE JOURNAL OF MEDICINE, 1961, 61 (06) : 885 - &
  • [35] The efficacy of adjuvant radioactive iodine therapy for patients with recurrent differentiated thyroid carcinoma
    Maskell, David
    Benson, Richard
    Harrison, Inge
    Barnett, Gill
    Jefferies, Sarah
    CLINICAL ONCOLOGY, 2018, 30 : E2 - E3
  • [36] Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma
    Lakhdar, Majdouline Bel
    Mouaden, Ayat
    Zekri, Mourad
    Alami, Dounia
    Zarouf, Hamza
    Ghfir, Imad
    Guerrouj, Hasnae
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2024, 23 (03) : 185 - 190
  • [37] MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
    Leboulleux, S.
    Benisvy, D.
    Taieb, D.
    Attard, M.
    Bournaud, C.
    Terroir, M.
    Al Ghuzlan, A.
    Lamartina, L.
    Schlumberger, M. J.
    Godbert, Y.
    Borget, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S1204 - S1204
  • [38] Radioactive Treatment in Patients With Metastatic Well-Differentiated Thyroid Cancer
    Karasawa, K.
    Shimizuguchi, T.
    Murata, H.
    Kageyama, S.
    Tanaka, H.
    Machitori, Y.
    Chang, T.
    Fujii, M.
    Nihei, K.
    Hanyu, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S462 - S462
  • [39] Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer
    Stanciu, Adina Elena
    Hurduc, Anca Elena
    Stanciu, Marcel Marian
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2016, 76 (08): : 626 - 631
  • [40] FDG avidity of metastatic differentiated thyroid cancer is superior to radioiodine avidity in prediction of radioactive iodine therapy response.
    Kang, Seo Young
    Bang, Ji In
    Suh, Min Seok
    Chung, June-Key
    Lee, Dong Soo
    Kang, Keon Wook
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
12345